RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. RKLB
6. BLK
7. NOW
8. CAT
9. RXRX
10. MSFT

Go back to RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform

Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold

April 28, 2014 1:46 PM EDT

Needham & Company downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Strong Buy to Hold with a price target of $14.00.

Analyst Chad Messer comments, "OncoGenex reported negative top line data from the pivotal SYNERGY trial testing custersin on top of 1st line chemotherapy with docetaxel in patients... More

OncoGenex Pharmaceuticals (OGXI), Teva (TEVA) Said Phase III SYNERGY Trial Did Not Meet Primary Endpoint

April 28, 2014 7:05 AM EDT

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and OncoGenex Pharmaceuticals, Inc.(NASDAQ: OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone... More